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Preference elicitation studies reporting societal views on the relative value of
end‐of‐life treatments have produced equivocal results. This paper presents an
alternative method, combining Q methodology and survey techniques (Q2S)
to determine the distribution of 3 viewpoints on the relative value of end‐of‐life
treatments identified in a previous, published, phase of this work. These were
Viewpoint 1, “A population perspective: value for money, no special
cases”; Viewpoint 2, “Life is precious: valuing life‐extension and patient
choice”; and Viewpoint 3, “Valuing wider benefits and opportunity cost: the
quality of life and death.”
A Q2S survey of 4,902 respondents across the United Kingdom measured agree-
ment with these viewpoints; 37% most agreed with Viewpoint 1, 49% with
Viewpoint 2, and 9% with Viewpoint 3. Regression analysis showed associations
of viewpoints with gender, level of education, religion, voting preferences, and
satisfaction with the NHS.
The Q2S approach provides a promising means to investigate how in‐depth
views and opinions are represented in the wider population. As demonstrated
in this study, there is often more than 1 viewpoint on a topic and methods that
seek to estimate that averages may not provide the best guidance for societal
decision‐making.
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Legitimate arguments exist for eliciting societal values in relation to health care resource allocation given the roles of the
general public as tax payers and as the potential future beneficiaries (or not) of treatments. In health economics, the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 MASON ET AL.main approach to eliciting societal preferences for health care has been through preference elicitation studies. Preference
elicitation techniques such as willingness to pay, discrete choice experiments, or person trade‐off are based around par-
ticipants making trade‐offs between options, recognising the opportunity cost of the decisions they make. However, there
are challenges with the way these methods are designed. Typically, they focus on a small number of attributes and exam-
ine them ceteris paribus in hypothetically designed scenarios. This can lead to individual attributes being highlighted
and potentially a higher weight given to these than if all attributes were considered together (Baker, Bateman, et al.,
2010). The stylised nature of the scenarios presented in preference elicitation studies generally results in a small number
of attributes, which may not capture the issues that are of importance to the members of the public who are responding
to the questions. As a complement to these preference elicitation studies, there is need for a study design that can take a
more holistic view on what is important to members of the public in health care decision‐making.
One topic that could benefit from this more holistic approach is around societal views on the provision of life‐extend-
ing, end‐of‐life treatments. In England, the National Institute for Health and Care Excellence (National Institute for
Health and Clinical Excellence, 2009a, 2009b) introduced a policy that gave special consideration to end‐of‐life treat-
ments. This policy was a change from the standard practice that assumes health gains measured in the form of quality
adjusted life years (QALYs) are of equal value to all patients and for all disease types. With this end‐of‐life policy, QALY
gains from life‐extending, end‐of‐life treatments are weighted more highly than QALY gains from other types of treat-
ment. Evidence from decisions so far indicates a weight of approximately 1.7 that is being applied to these end‐of‐life
treatments (Longson & Littlejohns, 2009).
A factor in the decision to change the policy for life‐extending, end‐of‐life treatments was the claim that society
viewed end‐of‐life treatments as “different” or more valuable (Jack, 2014; Rawlins, Barnett, & Stevens, 2010). However,
at the time of this decision, there was little evidence that society viewed end of life this way. Following this, a number of
preference elicitation studies were conducted to gain insight into whether members of the public give additional weight
to life‐extending, end‐of‐life treatments. A recent review identified 17 preference elicitation studies (12 published follow-
ing the National Institute for Health and Clinical Excellence [NICE] change in policy) on this topic (Shah, 2016). Of
these 17 studies, seven found a positive premium for end of life, seven found no premium, and three reported mixed find-
ings. The mixed findings from these 17 studies may be a result of the different preference elicitation techniques, modes of
administration, or differences in the questions presented to respondents, such as the size of the health gain, life expec-
tancy, or the type of comparator presented.
However, it may also be that there is disagreement within society about the relative value of end‐of‐life treatments,
which the focus on individual attributes or the aggregation of individual values in a preference elicitation study does not
allow us to observe. There is a lack of in‐depth data on the nature of societal perspectives on the relative value of health
gains at the end of life—information that may help us to explain the reasons why findings differ. Research is required
that is capable of incorporating a broader range of attributes that may influence societal views. We contend that surveys
underpinned by such qualitative prework, to establish “what matters” before measurement, are more likely to be robust.
In a project funded by the Medical Research Council Methodology Panel (G1002324), we conducted two interlinked
studies. The objective of the first study was to identify and describe societal perspectives on the relative value of life‐
extending, end‐of‐life treatments. Three viewpoints were identified and are briefly described in the next section and
reported in full in McHugh et al. (2015). The objectives of the second study were to determine the distribution of these
perspectives in a nationally representative sample of the U.K. population. This type of information is important if
policymakers want to be responsive to public values when making decisions on developing new or reforming current
guidance. This paper presents the findings of this second study. In what follows, we outline the first phase of our
research, which used Q methodology to identify the three societal viewpoints of concern here. Following this, we detail
how the results from the initial Q study were used to develop a survey, which was delivered online to 4,902 participants,
quota sampled to reflect the U.K. population on key demographics. We present our findings with respect to distributions
of the three societal viewpoints across the population. Finally, we discuss both methodological innovations and chal-
lenges and reflect on the policy implications of our results.2 | PRIOR Q STUDY
Q methodology combines qualitative and quantitative techniques to systematically study in‐depth, subjective views on a
given subject (Watts & Stenner, 2012). As noted above, Q methodology was used to elicit and describe three viewpoints
on the relative value of life extensions for people with terminal illness (McHugh et al., 2015). In brief, 59 respondents,
MASON ET AL. 3purposively selected on the basis of their experiences, associations, or expertise, took part in a ranking exercise, ordering
a set of 49 statements of opinion onto a grid. The grid comprised a corresponding number of 49 spaces presented in a
pyramid or quasi‐normal distribution shape. Respondents were asked to rank the statements from “most agree” on
the right hand side of the grid to “most disagree” on the left hand side. The statement set was derived from primary
and secondary sources including interviews, the National Institute for Health and Clinical Excellence (2009a, 2009b)
public consultation on the end‐of‐life guidance and newspaper reports related to the provision of life‐extending treat-
ments for people with terminal illness (McHugh et al., 2015). By‐person factor analysis of the ranking data revealed three
different viewpoints as described as follows, (a) “A population perspective—value for money, no special cases,” (b) “Life
is precious—valuing life‐extension and patient choice,” and (c) “Valuing wider benefits and opportunity cost—the qual-
ity of life and death.”
These three viewpoints form the basis for what follows and so are described in some detail here. The first viewpoint,
A population perspective—value for money, no special cases, is a broadly utilitarian, system‐level perspective. People asso-
ciated with this point of view place importance on maximising health benefits to a population, recognising that there is a
fixed health budget. According to this account, treatments yielding the greatest health improvements in relation to cost
should be prioritised, as they would offer good value for money, and all patient groups must be considered equally
deserving of treatment. It follows that life‐extending treatments for terminally ill patients would not usually be regarded
as a cost‐effective use of resources, because health gains are typically small, and new treatments are often expensive.
From this point of view, health gains for terminally ill patients are not treated as a special case and, to do so, would
devalue the health of all other patients.
The second viewpoint, Life is precious—valuing life‐extension and patient choice, places the individual patient at the
centre of decisions and is grounded in rights‐based arguments and views about entitlement. Central to this perspective is
that human life is precious and that the cost of treatments should not determine provision. Patient choice should be the
primary focus, and treatments must be provided if a patient chooses because everyone contributes to the funding of a
public health care system. Specifically, the denial of life‐extending treatments to patients who want them is regarded
as morally wrong as it does not account for patients' preferences, and the nonhealth benefits that these treatments might
have for patients or their families, such as time to prepare for death, put affairs in order, or say goodbye. However, pro-
vision of end‐of‐life treatments would not be treated as a special case when making coverage decisions as the key criteria
is that if a patient wants a treatment, including life‐extending treatments at the end of life, they should have it.
The third viewpoint, Valuing wider benefits and opportunity cost—the quality of life and death, like the first, places
great emphasis on achieving best value for money with respect to limited resources, and so withholding cost‐ineffective
treatments is consistent with this account. However, in this viewpoint, there is an appreciation that there may be value
for patients and their families from other nonhealth benefits not captured in standard cost per QALY calculations. As
such, there is room in this third account for special cases. The value attached to nonhealth benefits could mean that
improvements in quality of life or life extension at the end of life are more valuable than health gains for patients with
nonterminal conditions but that all treatments at the end of life are not more valuable per se.3 | METHODS
3.1 | Survey design
Building on the findings of the first study, we designed a survey to measure societal support for the three viewpoints
identified. The aim of Q‐based survey design (Q2S) is to extract, from the findings of an initial Q study statements that
distinguish viewpoints from one another. These statements act as “markers” for those viewpoints and are used as an
indication that survey respondents are more likely to agree with a particular viewpoint. The Q2S approach has been pre-
viously attempted in a small number of studies in the field of health economics (Baker, Wildman, Mason, & Donaldson,
2014; Mason, Van Exel, Baker, Brouwer, & Donaldson, 2016) but remains methodologically developmental (Baker, Van
Exel, Mason, & Stricklin, 2010). To select statements that best signal agreement with the original viewpoints, there are
two important considerations: salience and distinction. Salient statements are those which respondents who were highly
associated with the viewpoint cared strongly about (i.e., ranked most agree or most disagree). Distinguishing statements
are those which set each viewpoint apart (i.e., statements that are ranked statistically significantly differently for one
viewpoint compared to another). Statements selected for the survey can be positively or negatively associated with a
viewpoint but should be associated with only one and not the others. For example, considering agreement (or not) with
the statements that distinguish Viewpoint 1 would indicate probable agreement with that “whole” viewpoint. The six











(−5 to +5 scale)
V1 V2 V3
Viewpoint 1
3. Treatments should be directed towards people who have a greater chance of survival. 3 −1 0
5. At the end of their life, patients should be cared for at home with a better quality of life rather
than have aggressive and expensive treatments that will only extend life for a short period of time.
4 0 1
26. It is wrong to raise hopes and expectations by making a special case for treatments that will only
extend life by a short time.
3 −2 0
38. The health system should be about getting the greatest benefit overall for the population. 5 0 2
2. We should support an individual patient's choice for treatments that give short life extensions. −3 3 −1




17. If a life‐extending treatment for terminally ill patients is expensive, but the only treatment available,
it should still be provided.
−3 3 −3
20. We all have the right to life. 1 4 −1
27. To extend life in a way that is beneficial to the patient is morally the right thing to do. −1 3 0
37. All human life is precious. 1 5 0
1. It is not worthwhile devoting more and more NHS money to someone who is going to die soon
anyway.
0 −5 2
33. End‐of‐life drugs are not a cure, they are life‐prolonging. There is no point in delaying the inevitable
for a short time.
1 −4 −2
Viewpoint 3
25. We should spend proportionately more on patients when we feel those patients have not had their
fair innings—in terms of the length of their life or the quality of that life.
−3 −1 2
31. Treatments that are very costly in relation to their health benefits should be withheld. 1 −5 3
34. Patients at the end of life will grasp any slightest hope but that is not a good reason for the NHS to
provide costly treatments that may extend life by a short time.
2 −3 4
41. I would not want my life to be extended just for the sake of it—just keeping breathing is not life. 3 0 5
23. A year of life is of equal value for everyone. 0 0 −4
24. You cannot put a price on life. 0 3 −3
Note. Grey shaded statements are negatively associated with the viewpoint.
4 MASON ET AL.statements do not summarise the whole viewpoint and should not be interpreted as a summary of the full ranking of all
49 statements from the original Q study. These six statements are used to signal likely agreement with that view. Apply-
ing this method, we identified 18 statements (six for each viewpoint) from the original Q study to include in the survey.
Table 1 lists the 18 statements together with their position in each viewpoint in the original analysis to show how they
differ for each viewpoint.
The survey was delivered online. To introduce the survey, a short animation was created.1 This explained the premise
of the survey to respondents and the context of there being limited resources for health care and a need to make deci-
sions about which treatments and services will be provided. It went on to explain that there are many different things
that could be considered when making decisions about how best to allocate resources, such as severity of illness or qual-
ity of life, and that in this research, the focus was on treatments that help terminally ill patients live longer.
Following the video, the 18 statements were presented, three per screen (one per factor) in random order, and
respondents were instructed to indicate their agreement with each statement on a Likert scale labelled completely1The short animation can be found here: http://www.gcu.ac.uk/endoflife/onlinesurvey/introductoryanimation/.
MASON ET AL. 5disagree (1) to completely agree (7).2 The results reported here are from one section of a longer questionnaire in which
different approaches to Q2S survey design and policy choice questions were devised.
Following the completion of the survey, respondents were presented with 15 further general questions. These
included standard demographics such as age, gender, and income along with characteristics that could plausibly relate
to respondents' viewpoints, including voting preferences, religion, satisfaction with the NHS, and experience with termi-
nal illness as of May 2014 (the full list is presented in Table A1).
To test the validity of our survey instrument, a subsample of 134 people was recontacted and asked to complete a full
Q sort. The purpose of this external validity test was to check directly if the viewpoint that we aligned a respondent to
using the Q2S survey was the same viewpoint that they would have been aligned with if they ranked all 49 statements
in the Q sort. Results for both approaches were computed and correlations between the two compared. The results of the
validity test are presented in Section 4.3.2 | Data collection
The online survey was programmed and delivered by YouGov (www.yougov.co.uk) in May 2014. Respondents were
quota sampled from their online panel to reflect the make‐up of the U.K. population3 in terms of age, gender, ethnicity,
and socio‐economic status.3.3 | Analysis
In an attempt to exclude respondents who may not have fully engaged with the online survey, those who completed the
whole questionnaire very quickly (less than 7 min and 30 s) or very slowly (longer than 2 hr) were excluded from the
analysis. Although these cut‐offs are arbitrary, and it is possible that we excluded valid and considered responses, the
research team tested and timed the survey and judged those completing faster than 7 min and 30 s as unlikely to have
read and processed all information presented. Likewise, we made a judgement that those who spent more than 2 hr on
the survey may not have been fully engaged and may not fully recall the aim of the survey outlined in the animated
introduction when they first started.
Following the collection of the data, Cronbach's α was calculated to test the internal consistency of the six statements
representing each viewpoint. This analysis indicated that Statement 25 (see Table 1) did not share the same underlying
construct as the other five statements selected to represent Viewpoint 3. Therefore, scores for Statement 25 were not
used, and the remaining five statements were used in the analysis. For Viewpoints 1 and 2, all six statements were
retained for the analysis. Scores for the “negative” statements were inverted before further analysis was conducted, so
that all scores were on the same scale.
Each individual's Likert scale scores (between 1 and 7) were summed for the block of statements related to each view-
point. This gave each respondent a score between 6 and 42 for Viewpoints 1 and 2 and between 5 and 35 for Viewpoint 3.
To account for the differential number of statements representing Viewpoint 3, the total scores per viewpoint were
rescaled linearly between 0 and 10. Finally, respondents were “assigned” to one of the original three viewpoints based
on which viewpoint resulted in the highest score. Respondents who scored less than 4 (out of 10) on all viewpoints were
excluded from further analysis. To gain a total score under 4, respondents would have had to rate the majority of the
statements in the “disagree” end of the Likert scales, indicating that they could not find their views represented in
any of the statements. Therefore, it seemed inappropriate to assign them to one of the three viewpoints and were thus
removed from further analysis.
Multinomial logistic regression (MNL) was used to examine the relationship between respondents' viewpoints, as
assigned above, and their sociodemographic characteristics and responses to the follow‐up questions as outlined in Table
A1. MNL was used for the analysis because the dependent variable can take more than two, not logically ordered, discrete
values, in this case Viewpoints 1, 2, or 3. Viewpoint 1 was chosen as the comparator (against which others are compared)
because it best represents current NICE decision‐making for all other non‐end‐of‐life technologies, and gaining insight into
the particular characteristics or experiences of those not associated with this viewpoint would aid our understanding of2The survey is accessible at http://www.gcu.ac.uk/endoflife/onlinesurvey/q2ssurveyapproach1/.
3We recognise that online respondent panels cannot be said to be representative of the wider population (in the same way that survey respondents,
focus group participants, and all methods are subject to degrees of self‐selection bias) but aimed nonetheless, to represent key characteristics in propor-
tion to the general population.
6 MASON ET AL.why they hold a divergent point of view from current policy. Those with an equal highest score on more than one view-
point (categorised as “mixed”) were excluded from the MNL regression analysis due to the small numbers. The variables
listed in Table A1 were included in the regression analysis, but for concise presentation, only the variables that were sig-
nificant at the 10% level are included in Table 4. The relative risk in this case indicates the change in likelihood of being
associated with a viewpoint, for a one unit increase in the independent variable when all other variables remain constant.3.4 | Sensitivity analysis with exemplars
Respondentswere generally assigned to a single viewpoint based on the viewpoint associatedwith their highest total Likert
score (once adjusted for the number of statements as previously outlined). The decision to allocate respondents to a single
viewpoint based on highest score was a pragmatic one, to allow us to examine the prevalence of the viewpoints within the
sample. However, respondents have a score for all three viewpoints, and in some cases, these scores may be very close.
With that in mind, we identified a subsample of respondents who might be regarded as “exemplars” for a viewpoint. This
is a concept drawn from Qmethodology, where exemplars are respondents who most “purely” associate with a viewpoint.
To select exemplars, we calculated the average score for each viewpoint across the whole sample. Exemplars were
then defined as those with a score greater than the mean for one viewpoint, and scores on the other two viewpoints were
less than their highest score by 1.5 points (on the 0–10 scale). For example, the mean rescaled score for Viewpoint 1 was
6.0. To be defined as an exemplar of Viewpoint 1, a respondent had to have a maximum score for Viewpoint 1 greater
than or equal to 6 and scores for both Viewpoints 2 and 3 at least 1.5 points lower than the score for Viewpoint 1.
As a form of sensitivity analysis, we examined the relationship between respondent characteristics and viewpoints
based on this “exemplar subsample” only. We compared these findings with those from the whole—“highest score”
rule—sample, to test whether the associations of viewpoints with characteristics are robust.3.5 | Ethics
Ethical approval for this study was obtained from the School of Health and Life Sciences Ethics Committee, Glasgow
Caledonian University (Reference B11/04).4 | RESULTS
4.1 | Sample
The total number who completed the survey was 5,496. The application of the exclusion criteria based on time to com-
plete the survey excluded 566 respondents; 21 incomplete respondents were also excluded; and 7 scoring less than 4 on
all statements were excluded. These exclusions resulted in a final sample of 4,902, which is presented in Table 2 by sam-
pling variables. A full description of the sample, by response to each of the 15 questions included at the end of the survey,
is given in Table A1.4.2 | External validity testing
The correlation between the survey scores on each viewpoint and the full Q sort was .74. If we took the results of the full
Q sort as being the respondents' “true” viewpoint, the survey correctly predicted which viewpoint a respondent was
aligned with 74% of the time. This seems to indicate a good overall level of alignment between the survey instrument
and the full Q sorts.4.3 | Summary statistics
Descriptive statistics for each viewpoint are presented in Table 3. Paired sample tests compare the means for each view-
point (1 and 2, 2 and 3, and 1 and 3). This test shows that all means were statistically significantly different (p < .001)
from zero. Figure 1 shows the distribution of scores for each viewpoint. For all viewpoints, the distribution was left
skewed, but this pattern can be seen more clearly for Viewpoint 2 where approximately 6% of those associated with this
viewpoint scored 10 compared with less than 2% and less than 1% for Viewpoints 1 and 3, respectively. Descriptive sta-
tistics for each statement are presented in Table A2.
TABLE 2 Sociodemographic characteristics of respondents by matched viewpoints
Variables Total sample Viewpoint
1 2 3 Mixed p
N % N %^ N % N % N %
4,902 1,806 36.8 2,416 49.3 449 9.2 231 4.7
Age <.001**
18–29 761 15.5 205 11.4 421 17.4 81 18.0 54 23.4
30–49 1,642 33.5 517 28.6 907 37.5 133 29.6 85 36.8
50–64 1,304 26.6 520 28.8 602 24.9 138 30.7 44 19.0
65–74 678 13.8 309 17.1 296 12.3 48 10.7 25 10.8
75+ 517 10.5 255 14.1 190 7.9 49 10.9 23 10.0
Gender <.001**
Male 2,438 49.7 963 53.3 1,096 45.4 254 56.6 125 54.1
Female 2,464 50.3 843 46.7 1,320 54.6 195 43.4 106 45.9
Education <.001**
Low education 1,263 25.8 472 26.1 649 26.9 76 16.9 66 28.6
Middle education 1,257 25.6 451 25.0 613 25.4 134 29.8 59 25.5
High education 2,253 46.0 847 46.9 1,082 44.8 232 51.7 92 39.8
Income .109
Low income 1,222 24.9 452 25.0 605 25.0 95 21.2 69 29.9
Middle income 1,405 28.7 534 29.6 686 28.4 120 26.7 65 28.1
High income 1,067 21.8 407 22.5 509 21.1 118 26.3 33 14.3
Ethnicity <.001**
White 4,437 90.5 1,682 93.1 2,147 88.9 409 91.1 199 86.1
Non‐White 365 7.4 101 5.6 212 8.8 27 6.0 25.0 10.8
Country .094*
England 4,065 82.9 1,471 81.5 2,011 83.2 386 86.0 197 85.3
Wales 243 5.0 103 5.7 117 4.8 12 2.7 11 4.8
Scotland 513 10.5 207 11.5 245 10.1 44 9.8 17 7.4
Northern Ireland 81 1.7 25 1.4 43 1.8 7 1.6 6 2.6
Socio‐economic group (SEG) .206
AB (SEG) 1,464 30.0 559 31.1 705 29.3 156 34.9 44 19.1
C1 (SEG) 1,469 30.1 536 29.8 716 29.7 136 30.4 81 35.2
C2 (SEG) 807 16.5 295 16.4 410 17.0 61 13.6 41 17.8
DE (SEG) 1,144 23.4 410 22.8 576 23.9 94 27.8 64 27.8
Note. NB: For some questions there was an option to answer “do not know” or “prefer not to say,” these responses are not included in the table and may affect the
numbers adding up to the total sample.
**1% significance level.
*10% significance level.
^%'s are those within viewpoint, for example, 53.3% of those aligned with Viewpoint 1 are male.
The bold type indicated the results of the full sample. The non‐bold type are the results by Viewpoint.
TABLE 3 Summary of rescaled Likert scores by viewpoint
Descriptive statistics Correlations
N Range Mean SD Med Skewness Kurtosis Viewpoint 2 Viewpoint 3
Viewpoint 1 4,902 0–10 6.34 1.74 6.39 −0.197 −0.117 −.676 .698
Viewpoint 2 4,902 0–10 6.60 2.06 6.67 −0.284 −0.361 −.776
Viewpoint 3 4,902 0–10 4.89 2.07 5.00 −0.122 −0.363
Note. SD = standard deviation.
MASON ET AL. 74.4 | Prevalence of viewpoints
The majority of respondents (95.3%) had a maximum score on either Viewpoints 1, 2, or 3: 36.8% (n = 1,806) of respon-
dents were matched with Viewpoint 1 (A population perspective—value for money, no special cases); 49.3% (n = 2,416)
were matched with Viewpoint 2 (Life is precious—valuing life‐extension and patient choice); and 9.2% (n = 456) were
FIGURE 1 Distribution of scores, by viewpoint [Colour figure can be viewed at wileyonlinelibrary.com]
8 MASON ET AL.matched with Viewpoint 3 (Valuing wider benefits and opportunity cost—the quality of life and death). The remaining
respondents (4.7%, n = 231) had equal maximum scores (all of 5 or above) for more than one viewpoint (and were
assigned to the category mixed).4.5 | Examining the relationship between viewpoints and other respondent
characteristics
The results of the MNL regression analysis presented in Table 4 indicate that associations with different viewpoints were
linked to some individual characteristics. Relative to respondents assigned to Viewpoint 1, those assigned to 2 were more
likely to be female, belong to a religion, vote labour, have a lower education level and be more dissatisfied with the NHS.
Respondents assigned to Viewpoint 3 were more likely to have a higher education level and be more dissatisfied with the
NHS but less likely to be female and to belong to a religion.
ABLE 4 Relationship between the viewpoints and respondents' characteristics
Characteristic
Viewpoint^
2N = 2,416 3N = 449
RRR p RRR p
Age (years) 0.98 (0.97–0.98) <.001*** 0.99 (0.98–1.00) .004***
Sex (female) 1.21 (1.06–1.37) <.001*** 0.81 (0.67–1.01) .062*
Education level (low = no qualifications to pre‐GCSE, middle =
GCSE to diploma, or high = undergraduate degree and above)
0.91 (0.84–0.98) .014** 1.18 (1.03–1.35) .018**
Religion: Do you regard yourself as belonging to any particular
religion? Yes or no.
1.53 (1.34–1.75) <.001*** 0.67 (0.53–0.84) <.001***
Over 65 s in household (yes or no) 1.18 (0.99–1.41) .056* 0.98 (0.73–1.32) .889
Satisfaction with NHS—1 = very satisfied to 5 = very dissatisfied 1.13 (1.06–1.21) <.001*** 1.15 (1.03–1.28) .013**
Conservative voter 0.67 (0.57–0.79) <.001*** 1.17 (0.91–1.50) .232
Labour voter 1.38 (1.18–1.62) <.001*** 0.98 (0.74–1.29) .896




Viewpoint 1 is the comparator.





^4.6 | Identifying exemplars
Following the methods outlined in the analysis section, 2,423 respondents were identified as exemplars, with 651 (27%)
exemplar respondents for Viewpoint 1; 1,701 (70%) for Viewpoint 2; and 71 (3%) for Viewpoint 3. Using this subset of
individuals in the MNL analysis, we can compare those who are most strongly and purely associated with each viewpoint
and their characteristics. The results are shown in Table 5.
For Viewpoint 3, belonging to a religion is now the only statistically significant variable. However, it should be noted
that the number of exemplars associated with Viewpoint 3 is only 71. Generally, the results for Viewpoint 2 were very
similar to the original analysis presented in Table 4; only having over 65 s in the household was no longer statistically
significant.5 | DISCUSSION
This paper reports the findings of a survey based on a prior Q‐methodology study, investigating the distribution of soci-
etal viewpoints with respect to the provision of life‐extending treatments for people with terminal illness. We found two
dominant viewpoints (1 and 2) that were preferred by 37% and 49% of the respondent sample, respectively. There was
less support for Viewpoint 3 (9%). This reflects a well‐documented, ethical “divide” between a broadly utilitarian per-
spective that focuses on maximising health outcome in the context of a fixed budget and a perspective based on patient
choice and entitlement to health care that would likely result in an increased health budget, if operationalised.
These results could be seen as presenting a dilemma for policymakers as they indicate that there is not a majority
viewpoint. This is not necessarily to suggest that policy making should be majoritarian, or that the viewpoint that is most
common amongst respondents is the only legitimate basis for policy—but, we would argue, that both the nature of social
perspectives on a given policy topic and the level of agreement with those perspectives in the wider population are
important pieces of information in devising policies. The identification of two well‐supported viewpoints, in itself, could
be viewed as important new knowledge. There are dominant voices in the debate around the provision of life‐extending,
end‐of‐life treatments that mirror Viewpoints 1 and 2. A number of claims have been made about the views of the gen-
eral public, generally in support of giving additional priority to treatments for cancer or terminal illness (Jack, 2014;
Rawlins et al., 2010). However, this has often been conjecture, based on the lack of protest from other patient groups,
or the general public more widely, to changes in policy.
This project (including the paper by McHugh et al., 2015) was designed to identify, describe, and examine the distri-
bution of societal values in relation to the provision of life‐extending treatments for people with terminal illnesses. The
results indicate that current policies including the NICE End‐of‐Life Guidance and the Cancer Drug Fund in England
TABLE 5 Relationship between those strongly associated with the viewpoints and respondents characteristics
Characteristic
Viewpoint^
2N = 1,701 3N = 71
RRR p RRR p
Age (years) 0.97 (0.96–0.97) <.001*** 0.99 (0.97–1.00) .130
Sex (female) 1.25 (1.03–1.52) .024** 0.66 (0.39–1.11) .130
Education level (low = no qualifications to pre‐GCSE, middle =
GCSE to diploma, or high = undergraduate degree and above)
0.89 (0.80–1.00) .062* 1.13 (0.82–1.55) .452
Religion: Do you regard yourself as belonging to any particular
religion? Yes or no.
1.77 (1.44–2.17) <.001*** 0.57 (0.32–1.02) .057*
Over 65 s in household (yes or no) 1.09 (0.84–1.40) .521 0.60 (0.28–1.29) .188
Satisfaction with NHS—1 = very satisfied to 5 = very dissatisfied 1.16 (1.05–1.28) <.001*** 1.14 (0.89–1.47) .291
Conservative voter 0.62 (0.48–0.78) <.001*** 1.22 (0.67–2.24) .520
Labour voter 1.42 (1.12–1.81) <.001*** 0.98 (0.51–1.89) .957




^Viewpoint 1 is the comparator.
10 MASON ET AL.would find very little support and that the viewpoints suggest what type of policies might find traction in the U.K. public.
Viewpoint 2 suggests that end‐of‐life treatments should be provided if patients choose them, but it does not make end of
life a special case as these policies do, instead all treatments should be available if patients wish to have them—a view
that would require increases in the health budget. In Viewpoint 3, life extension for people with a terminal illness may be
valued more than the health gains for patients with nonterminal illness, but the standard approaches to assessing health
benefits do not fully capture these for use in the decision‐making process. Only one in 10 of our sample most agreed with
Viewpoint 3, which could be considered to be more nuanced and technical, focussing on the specifics of how we measure
wider benefits of health interventions. It is possible that people who have not thought about this issue before, completing
a survey might tap into the broad distinctions of Viewpoints 1 and 2, and thus, Viewpoint 3 receives less general support
in a larger general public sample.
Although these results may not support current policies, they do raise challenges for decision‐making. Viewpoint 2 in
particular, grounded in patient choice, would necessitate growing the health care budget. In both phases of this work, the
introduction to the survey stressed that the NHS has a limited budget and that decisions need to be made about how best
to spend this. Despite this, Viewpoint 2 rejects the traditional health economics approaches to decision‐making that con-
siders costs and outcomes together to provide interventions that are good value for money. Viewpoint 2 is most certainly
an account that rejects cost as a deciding factor—and that is problematic (for health economists and for policymakers),
but the qualitative data shone a different light on its interpretation. What appeared to be a denial of resource constraint
altogether, and perhaps misunderstanding of the issues, was shown in the qualitative data (as reported in McHugh et al.,
2015), to be a political argument that in a rich country we can afford more—political decisions determine the size of the
budget, and other decisions are possible. On the basis of the qualitative findings, we interpret this as a relevant and not a
confused account. It feels counterintuitive to us as health economists who are used to designing preference elicitation
studies that do not allow for a response like Viewpoint 2. However, as the introductory sections of the paper show, there
is a very mixed empirical literature on end of life. The intention in this programme of work was to try and gain insight
into why this might be the case. By allowing respondents to express a view that may seem “irrational” considering the
premise of the survey, we have generated new knowledge that would not emerge from standard preference elicitation
studies. The statements in the Q set come from in‐depth interviews, and so it could be argued that the viewpoints
revealed in this work are more “emergent” or grounded in data rather than imposed by constraints built into our study
design. We take the view that, however, inconvenient Viewpoint 2, it is important to understand it. We agree that it is not
operational in a policy sense within the short term, but it is surely better to know about these views so that they can at
least be addressed in policy discourse.
With the increasing importance of involving the public in health care decision‐making, there is an opportunity for work
like this to be used to inform selection of participants for public and patient involvement in groups such as NICE's Citizen
Council. Instead of sampling in a way that aims to approximate different views via sociodemographic and other
MASON ET AL. 11characteristics, participants could be selected to represent a range of perspectives on the issues at stake. The results of our
MNL regression analysis indicated that there were only a small number of sociodemographic characteristics that influenced
that the viewpoint respondents weremost associated with. Thus, selection of participants for groups like the Citizen Council
based on sociodemographic characteristicsmaynot be inclusive of the full range of views that exist on issues thatwould guide
resource allocation. Surveys such as the one presented in this paper could be used as a selection tool, along with other sam-
pling procedures based on sociodemographics, so that there is a balance of viewpoints in the participants selected.
This project also had a methodological aim and has contributed to the development of Q2S methods. Q2S is still a
relatively unused approach to eliciting societal views in large samples, with only a small number of published applica-
tions of Q‐based survey methods (Brown, 2002; Mason et al., 2016; Talbott, 1963). The use of Likert scales to score state-
ments has been previously used in only two studies with difficulties in presenting the methods of analysis acknowledged
(Baker, Bateman, et al., 2010; Baker, Van Exel, et al., 2010); therefore, a new approach to analysis was designed for this
study. The approach taken to assign respondents to a viewpoint based on highest score was somewhat pragmatic,
allowing us to categorise respondents in order to examine the support for each viewpoint. However, a limitation of this
approach is that we lose information on respondent's strength of association with each of the viewpoints. To investigate
how strength of association with each viewpoint may influence our overall results, we conducted the “exemplar analy-
sis.” In future research, we will build on these methods and look to other fields, such as electoral voting systems, to incor-
porate into the design and analysis of Q2S methods the fact that individuals can be associated (to different degrees) with
more than one viewpoint.
As in all empirical studies, there are a number of strengths and limitations of the methods. Large scale attitudinal or
valuation surveys are often designed according to attributes thought to be of interest or based in theoretical concepts. A
strength of this work is that the constructs measured in this survey emerge directly from empirical research. The three
views that form the basis of this survey arose from the previous Q study, which combined qualitative and quantitative ele-
ments. This allowed us to explore in depth what views exist on the relative value of life‐extending treatments for people
with terminal illness. However, the Q2S design rests on the premise that associationwith awhole viewpoint can be approx-
imated by selecting key aspects of that viewpoint and using those as indicators of the whole viewpoint. This is somewhat
contentious in Qmethodological terms, where the emphasis is on interpretation of the viewpoints based on the placement
of all of the statements. Extracting statements from that set, it could be argued, alters their meaning, and therefore, one
criticism of this approach is that salient and distinguishing statements cannot be used in isolation to signal agreement with
a more complex perspective. The external validity testing outlined in Section 3 indicated that there is reasonably good
alignment between the viewpoints that we would expect a respondent to be aligned to based on the results of their full
Q sorts and the survey. This was particularly the case for Viewpoint 2. Examining the correlations between the survey
results and the full Q sort according to each viewpoint, the correlation for Viewpoint 2 was higher at .8, and the survey cor-
rectly predicted 85% of the respondents aligned with Viewpoint 2 in the Q study. For Viewpoints 1 and 3, the correlations
were lower at .75 (73% correctly predicted) and .71 (44% correctly predicted), respectively. The ability to distinguish
between respondents aligned with Viewpoints 1 and 3 may be lower in this survey as a result of a high correlation of .68
between Viewpoints 1 and 3 in the initial Q study. Viewpoints 1 and 3 have in common a central focus on achieving value
for money. However, for Viewpoint 3, quality of life is a crucial focus, and its value is interpreted more widely, although in
both accounts, technologies should not be provided if there is not significant benefit, even if that means denying patients
access to certain treatments. This high correlation impacted on the survey design as it resulted in a smaller number of
statements that were both distinguishing and salient for Viewpoint 3. Given the approach to scoring each viewpoint, this
could potentially have led to respondents who would have been aligned with Viewpoint 3 in a Q sort being categorised as
Viewpoint 1 or mixed, thus underestimating the prevalence of Viewpoint 3.
The statements that were used in both the Q study and this survey were designed to cover the range of opinions that
exist on the relative value of end‐of‐life treatments, and as such, some can be quite complex. The statements were
piloted as part of the Q study, but in this Q2S survey where respondents only saw a selection of statements and com-
pleted a less intensive task, it may have created less engagement and therefore less awareness of the implications of
their choices.
The design of this survey used Likert scales as the method to score each statement as the data that they provide can be
used flexibly and they are common in survey research. However, Likert scales do not force the participant to make trade‐
offs as is the case inQmethodology studies where statements must be rank ordered. The selection of statements asmarkers
for different viewpoints results in a group of statements that could be seen as quite contradictory; thus, if participants gave
the same score to all statements, it is likely to indicate that they have not engaged with the exercise, and we removed these
participants from the final analysis. Other Q‐based survey approaches that did require participants to rank statements were
12 MASON ET AL.tested as part of this programme of work but are not presented here (these can be accessed at http://www.gcu.ac.uk/
endoflife/onlinesurvey/). Participant engagement was also assessed through the use of the time taken to complete the
survey. Participants who completed the survey very fast (<7.5min) or slowly (>2 hr) were excluded from the final analysis.
This is an imperfect way to assess engagement, and there may be respondents close to the thresholds who did not engage
well but were included in the data set as well as engaged but slow participants who were excluded.
This approach can be viewed as a complement to traditional preference elicitation studies such as those described in
Section 1. The first phase of this work highlighted that there are multiple viewpoints in relation to the relative value of
life‐extending treatments, and in this study, we have demonstrated that there is not one dominant viewpoint. This could
help to explain why the preference studies in this field have yielded such conflicting findings even if the results could be
considered problematic for health economists and policymakers.
This study has provided the most comprehensive examination of the Q2S approach to date while generating new
evidence on the views of the U.K. general public on a highly contested policy issue. The Q2S approach provides a
promising means to investigate how in‐depth views and opinions (which by their nature need to be captured through
smaller, qualitative studies) are represented in the wider population. This approach retains the plural nature of the views
that exists on a particular topic, which is an advantage of the Q2S approach. As demonstrated in this study, there is often
more than one viewpoint on a topic and methods that seek to estimate that averages may not provide the best guidance
for societal decision‐making (Van Exel, Baker, Mason, Donaldson, & Brouwer, 2015). Although we have demonstrated
the Q2S approach with examination of societal viewpoints on the relative value of treatments for people with a terminal
illness, this method can be used to study any topic where we expect there to be differing viewpoints within society, and
there is a policy interest to understand how strongly these views are supported within the wider public.ACKNOWLEDGEMENTS
The study was funded by the Medical Research Council (MRC) Methodology Panel (Project ID G1002324).CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.ORCID
Helen Mason http://orcid.org/0000-0002-9303-2794
Job Van Exel http://orcid.org/0000-0002-4178-1777
Rachel Baker http://orcid.org/0000-0002-3451-2018REFERENCES
Baker, R., Bateman, I., Donaldson, C., Jones‐Lee, M., Lancsar, E., Loomes, G., … Wildman, J. (2010). Weighting and valuing quality adjusted
life years using stated preference methods: Preliminary results from the Social Value of a QALY project. Health Technology Assessment, 14.
Baker, R., Van Exel, J., Mason, H., & Stricklin, M. (2010). Connecting Q & surveys: Three methods to explore factor membership in large sam-
ples. Operant Subjectivity, 34, 38–58.
Baker, R., Wildman, J., Mason, H., & Donaldson, C. (2014). Q‐ing for health—A new approach to eliciting the public's views on health care
resource allocation. Health Economics, 23, 283–297.
Brown, S. (2002). Q‐technique and questionnaires. Operant Subjectivity, 25, 117–126.
Jack, A. (2014). Peter Clark: Public attitudes support a more favourable assessment for cancer treatments. BMJ, 349, g5545–g5545.
Longson, C., & Littlejohns, P. (2009). Update report on the application of the “End‐of‐Life” supplementary advice in health technology appraisals.
London: National Institute for Health and Clinical Excellence.
Mason, H., Van Exel, J., Baker, R., Brouwer, W., & Donaldson, C. (2016). From representing views to representativeness of views: Illustrating a
new (Q2S) approach in the context of health care priority setting in nine European countries. Social Science & Medicine, 166, 205–213.
McHugh, N., Baker, R. M., Mason, H., Williamson, L., Van Exel, J., Deogaonkar, R., … Donaldson, C. (2015). Extending life for people with a
terminal illness: A moral right and an expensive death? Exploring societal perspectives. BMC Medical Ethics, 16.
National Institute for Health and Clinical Excellence 2009a. Appraising life‐extending, end of life treatments. Response to consultation.
London: National Institute for Health and Clinical Excellence.
MASON ET AL. 13National Institute for Health and Clinical Excellence 2009b. Appraising treatments which may extend life at the end of life. Supplementary
advice to the appraisal committees. London.
Rawlins, M., Barnett, D., & Stevens, A. (2010). Pharmacoeconomics: NICE's approach to decision‐making. British Journal of Clinical Pharma-
cology, 70, 346–349.
Shah, K. K. (2016). Does society place special value on end of life treatments? In J. Round (Ed.), Care at the end of life. An economic perspective
(1st ed.). London: Adis.
Talbott, A. (1963). The Q block method of indexing Q typologies. Lincoln, Nebraska: AEJ Convention.
Van Exel, J., Baker, R., Mason, H., Donaldson, C., & Brouwer, W. (2015). Public views on principles for health care priority setting: Findings of
a European cross‐country study using Q methodology. Social Science & Medicine, 126, 128–137.
Watts, S., & Stenner, P. (2012). Doing Q methodological research: Theory, method & interpretation. London: Sage.SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.
How to cite this article: Mason H, Collins M, McHugh N, et al. Is “end of life” a special case? Connecting Q
with survey methods to measure societal support for views on the value of life‐extending treatments. Health
Economics. 2018. https://doi.org/10.1002/hec.3640
